DK0707475T3 - Langsom frigørende, filmcoatet tablet af astemizol og pseudoephedrin - Google Patents

Langsom frigørende, filmcoatet tablet af astemizol og pseudoephedrin

Info

Publication number
DK0707475T3
DK0707475T3 DK94919620.8T DK94919620T DK0707475T3 DK 0707475 T3 DK0707475 T3 DK 0707475T3 DK 94919620 T DK94919620 T DK 94919620T DK 0707475 T3 DK0707475 T3 DK 0707475T3
Authority
DK
Denmark
Prior art keywords
pct
astemizole
coated tablet
pseudoephedrine
release
Prior art date
Application number
DK94919620.8T
Other languages
Danish (da)
English (en)
Inventor
Paul Marie Victor Gilis
Eugene Marie Jozef Jans
Guido Jozef Maria Gijs
Original Assignee
Janssen Pharmaceutica Nv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Pharmaceutica Nv filed Critical Janssen Pharmaceutica Nv
Application granted granted Critical
Publication of DK0707475T3 publication Critical patent/DK0707475T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK94919620.8T 1993-06-14 1994-06-07 Langsom frigørende, filmcoatet tablet af astemizol og pseudoephedrin DK0707475T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP93201697 1993-06-14

Publications (1)

Publication Number Publication Date
DK0707475T3 true DK0707475T3 (da) 1997-12-29

Family

ID=8213895

Family Applications (1)

Application Number Title Priority Date Filing Date
DK94919620.8T DK0707475T3 (da) 1993-06-14 1994-06-07 Langsom frigørende, filmcoatet tablet af astemizol og pseudoephedrin

Country Status (21)

Country Link
US (1) US5681582A (cs)
EP (1) EP0707475B1 (cs)
JP (1) JPH08511257A (cs)
KR (1) KR100337985B1 (cs)
CN (1) CN1071570C (cs)
AT (1) ATE158178T1 (cs)
AU (1) AU675557B2 (cs)
CA (1) CA2163121A1 (cs)
CZ (1) CZ284822B6 (cs)
DE (1) DE69405752T2 (cs)
DK (1) DK0707475T3 (cs)
ES (1) ES2107235T3 (cs)
FI (1) FI955979A7 (cs)
GR (1) GR3025550T3 (cs)
HU (1) HU219462B (cs)
NO (1) NO311918B1 (cs)
NZ (1) NZ268003A (cs)
SI (1) SI9420040A (cs)
SK (1) SK279684B6 (cs)
WO (1) WO1994028880A1 (cs)
ZA (1) ZA944162B (cs)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US5558879A (en) * 1995-04-28 1996-09-24 Andrx Pharmaceuticals, Inc. Controlled release formulation for water soluble drugs in which a passageway is formed in situ
EP0811374A1 (en) 1996-05-29 1997-12-10 Pfizer Inc. Combination dosage form comprising cetirizine and pseudoephedrine
US5895663A (en) * 1997-07-31 1999-04-20 L. Perrigo Company Pseudoephedrine hydrochloride extended-release tablets
FR2771291B1 (fr) * 1997-11-21 2000-02-25 Ethypharm Lab Prod Ethiques Spheroides, procede de preparation et compositions pharmaceutiques
DE19821625C1 (de) * 1998-05-15 2000-01-05 Merck Patent Gmbh Pharmazeutische Zubereitung
CA2341485A1 (en) * 1998-08-25 2000-03-02 Chris Platt Timed release tablet comprising naproxen and pseudoephedrine
EA004936B1 (ru) * 1998-12-24 2004-10-28 Янссен Фармацевтика Н.В. Препаративная форма галантамина с регулируемым выделением
US6432448B1 (en) 1999-02-08 2002-08-13 Fmc Corporation Edible coating composition
US6723342B1 (en) 1999-02-08 2004-04-20 Fmc Corporation Edible coating composition
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6251432B1 (en) 1999-07-01 2001-06-26 Abbott Laboratories Sustained release dosage form unit having latex coating and method of making the same
SE9903879D0 (sv) * 1999-10-28 1999-10-28 Ethical Pharmaceuticals Sweden Multipor food protection
US6500462B1 (en) 1999-10-29 2002-12-31 Fmc Corporation Edible MCC/PGA coating composition
IN192159B (cs) * 2000-05-15 2004-02-28 Ranbaxy Lab Ltd
US20020094345A1 (en) * 2000-10-06 2002-07-18 Sara Abelaira Pharmaceutical compositions containing epinastine and pseudoephedrine
AU2002225763A1 (en) 2000-11-28 2002-06-11 Fmc Corporation Edible pga(propylene glycol alginate) coating composition
US6932861B2 (en) 2000-11-28 2005-08-23 Fmc Corporation Edible PGA coating composition
US7125563B2 (en) 2002-04-12 2006-10-24 Dava Pharmaceuticals, Inc. Sustained release pharmaceutical preparations and methods for producing the same
KR100602235B1 (ko) * 2002-07-09 2006-07-19 한국맥널티 주식회사 방출제어형 약제학적 조성물의 제조방법
US6663892B1 (en) 2002-08-19 2003-12-16 L. Perrigo Company Multiple portion tablet
US7115283B2 (en) * 2003-05-06 2006-10-03 Access Business Group International Llc Preparations for sustained release of nutraceuticals and methods of controllably releasing nutraceuticals
US7713550B2 (en) * 2004-06-15 2010-05-11 Andrx Corporation Controlled release sodium valproate formulation
US8404697B2 (en) 2005-11-11 2013-03-26 Boehringer Ingelheim International Gmbh Quinazoline derivatives for the treatment of cancer diseases
US8173686B2 (en) 2006-11-06 2012-05-08 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168661B2 (en) * 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8178564B2 (en) * 2006-11-06 2012-05-15 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
US8168662B1 (en) 2006-11-06 2012-05-01 Poniard Pharmaceuticals, Inc. Use of picoplatin to treat colorectal cancer
JP2010518088A (ja) * 2007-02-09 2010-05-27 ポニアード ファーマシューティカルズ， インコーポレイテッド カプセル化されたピコプラチン
US20110033528A1 (en) * 2009-08-05 2011-02-10 Poniard Pharmaceuticals, Inc. Stabilized picoplatin oral dosage form
US20100260832A1 (en) * 2007-06-27 2010-10-14 Poniard Pharmaceuticals, Inc. Combination therapy for ovarian cancer
TW200916094A (en) * 2007-06-27 2009-04-16 Poniard Pharmaceuticals Inc Stabilized picoplatin dosage form
NZ586025A (en) * 2008-01-11 2012-08-31 Teva Pharma Rasagiline mesylate tablet coated with a composisiton comprising methacrylic acid - ethyl acrylate copolymer and triethyl citrate
TWI478712B (zh) 2008-09-30 2015-04-01 Astellas Pharma Inc 釋控性醫藥組成物
US8778398B2 (en) 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
US20100260842A1 (en) * 2009-04-06 2010-10-14 Rashmi Nair Pseudoephedrine pharmaceutical formulations
JP5963672B2 (ja) 2009-07-06 2016-08-03 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｂｉｂｗ２９９２、その塩及びこの活性成分を含む固体医薬製剤の乾燥方法
KR101193495B1 (ko) * 2010-02-01 2012-10-23 한미사이언스 주식회사 슈도에페드린 및 레보세티리진을 포함하는 경구용 복합 조성물
WO2011119839A1 (en) 2010-03-24 2011-09-29 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
WO2011122524A1 (ja) 2010-03-29 2011-10-06 アステラス製薬株式会社 放出制御医薬組成物
CN102247368B (zh) * 2011-05-19 2013-05-29 安徽永生堂药业有限责任公司 一种复方阿伐斯汀缓释片及其制备方法
CA2835364C (en) 2011-05-20 2018-10-02 Astrazeneca Uk Limited Pharmaceutical composition of rosuvastatin calcium
CN104023725B (zh) 2011-08-16 2019-04-26 卡迪欧拉有限公司 控释制剂
EP3236963B1 (en) 2014-12-22 2020-01-29 Cardiora Pty Ltd Method of treatment
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US12186296B1 (en) 2016-07-22 2025-01-07 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US20180263936A1 (en) 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
EP3883549A1 (en) 2018-11-19 2021-09-29 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
WO2020178695A1 (en) 2019-03-01 2020-09-10 Flamel Ireland Limited Gamma-hydroxybutyrate compositions having improved pharmacokinetics in the fed state
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
US12097189B1 (en) 2024-02-09 2024-09-24 Astellas Pharma Inc. Pharmaceutical composition for modified release

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
IL70071A (en) * 1982-11-01 1987-12-31 Merrell Dow Pharma Multilayered sustained release pharmaceutical tablets having non-uniform distribution of active ingredient
US4829064A (en) * 1987-06-08 1989-05-09 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4975426A (en) * 1987-06-08 1990-12-04 Analgesic Associates Cough/cold mixtures comprising non-sedating antihistamine drugs
US4996061A (en) * 1987-10-07 1991-02-26 Merrell Dow Pharmaceuticals Inc. Pharmaceutical composition for piperidinoalkanol-decongestant combination
CN1053570C (zh) * 1987-10-07 2000-06-21 默尔多药物公司 哌啶子基链烷醇的药用组合物-减充血剂复方的制备方法
US4999226A (en) * 1988-06-01 1991-03-12 Merrell Dow Pharmaceuticals Inc. Pharmaceutical compositions for piperidinoalkanol-ibuprofen combination
US4990535A (en) * 1989-05-03 1991-02-05 Schering Corporation Pharmaceutical composition comprising loratadine, ibuprofen and pseudoephedrine
US5595997A (en) * 1994-12-30 1997-01-21 Sepracor Inc. Methods and compositions for treating allergic rhinitis and other disorders using descarboethoxyloratadine
US6114346A (en) * 1999-10-22 2000-09-05 Schering Corporation Treating sleep disorders using desloratadine

Also Published As

Publication number Publication date
EP0707475A1 (en) 1996-04-24
FI955979A0 (fi) 1995-12-13
SI9420040A (en) 1996-08-31
DE69405752D1 (de) 1997-10-23
GR3025550T3 (en) 1998-03-31
KR100337985B1 (ko) 2002-11-23
ES2107235T3 (es) 1997-11-16
ZA944162B (en) 1995-12-13
CZ284822B6 (cs) 1999-03-17
NZ268003A (en) 1996-11-26
NO311918B1 (no) 2002-02-18
SK279684B6 (sk) 1999-02-11
AU675557B2 (en) 1997-02-06
HUT73768A (en) 1996-09-30
AU7071494A (en) 1995-01-03
CA2163121A1 (en) 1994-12-22
ATE158178T1 (de) 1997-10-15
CZ324595A3 (en) 1996-03-13
NO955027L (no) 1995-12-12
HU9501922D0 (en) 1995-09-28
HU219462B (hu) 2001-04-28
EP0707475B1 (en) 1997-09-17
CN1071570C (zh) 2001-09-26
JPH08511257A (ja) 1996-11-26
FI955979L (fi) 1995-12-13
SK155595A3 (en) 1997-02-05
DE69405752T2 (de) 1998-02-05
WO1994028880A1 (en) 1994-12-22
NO955027D0 (no) 1995-12-12
FI955979A7 (fi) 1995-12-13
CN1125396A (zh) 1996-06-26
US5681582A (en) 1997-10-28

Similar Documents

Publication Publication Date Title
DK0707475T3 (da) Langsom frigørende, filmcoatet tablet af astemizol og pseudoephedrin
FI922369A0 (fi) Preparat med foerdroejd frigoering.
BR9506903A (pt) Tablete de paracetamol e domperidona revestido com película
NO960373L (no) Stabilisert farmasöytisk preparat inneholdende bupropion
SE9402422D0 (sv) New beads for controlled release and a pharmaceutical preparation containing the same
MY112915A (en) Multiple unit tableted dosage form 1
SE9500422D0 (sv) New oral pharmaceutical dosage forms
ES2196620T3 (es) Formulacion de liberacion prolongada que contiene venlafaxina.
NO20010537L (no) Farmasøytiske preparater omfattende ibuprofen og domperidon
ATE173399T1 (de) Retardtablette mit einem gehalt an diclofenac-na
DK0863752T3 (da) Anvendelse af alkylaminderivater såsom terbinafin ved fremstillingen af et lægemiddel til behandling af ledsagende sygdomme af en helicobacter pylori-infektion.